Small Cell Lung Cancer Extensive Stage Clinical Trial
Official title:
Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease: a Randomized, Open-label, Multicenter Phase II Study
This is a multicenter phase 2 clinical trial to investigate the treatment efficacy and feasibility of combining thoracic radiotherapy (TRT) with the IMpower133 regimen in the upfront treatment of ED SCLC patients. Patients with a response after induction therapy with carboplatin/etoposide and atezolizumab will be included into this study to subsequently receive atezolizumab maintenance therapy and will be randomized to receive TRT or not. This trial aims to i.) increase the efficacy of combined atezolizumab- and chemotherapy by adding radiotherapy and ii.) determine the safety and tolerability of the combination of chemotherapeutic, immunological and radiological treatment in the first-line setting of advanced SCLC, and iii.) to collect tumor tissue as well as blood and stool samples for separate biomarker research project.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT02179528 -
Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)
|
Phase 2 | |
| Recruiting |
NCT06030258 -
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05384015 -
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05745350 -
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
|
Phase 2 | |
| Completed |
NCT03325816 -
Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05856695 -
A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)
|
Phase 2 | |
| Terminated |
NCT00003496 -
Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03059667 -
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03923270 -
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06348797 -
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
|
Phase 1 | |
| Recruiting |
NCT05680922 -
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT04967625 -
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
|
Phase 2 | |
| Recruiting |
NCT04659785 -
A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
| Not yet recruiting |
NCT05066945 -
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
|
||
| Recruiting |
NCT05945745 -
Molecular Analysis and Treatment Options of SCLC
|
||
| Not yet recruiting |
NCT03755115 -
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT05027867 -
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT06187740 -
Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy
|
Phase 1 | |
| Recruiting |
NCT03994744 -
Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC
|
Phase 2 |